We therefore set out to then examine if PDGFRA activation, due to amplification of the PDGFRA gene, an alteration frequently found in pediatric brain tumors (eg. gliomas and medulloblastomas) [13,14,47], affects regorafenib activity alone or in combination with DNA damaging agents. Here, PDGFRA is linked to medulloblastoma.